Literature DB >> 18846251

Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice.

Julia Yuen-Shan Tsang1, Yakup Tanriver, Shuiping Jiang, Shao-An Xue, Kulachelvy Ratnasothy, Daxin Chen, Hans J Stauss, R Pat Bucy, Giovanna Lombardi, Robert Lechler.   

Abstract

T cell responses to MHC-mismatched transplants can be mediated via direct recognition of allogeneic MHC molecules on the cells of the transplant or via recognition of allogeneic peptides presented on the surface of recipient APCs in recipient MHC molecules - a process known as indirect recognition. As CD4(+)CD25(+) Tregs play an important role in regulating alloresponses, we investigated whether mouse Tregs specific for allogeneic MHC molecules could be generated in vitro and could promote transplantation tolerance in immunocompetent recipient mice. Tregs able to directly recognize allogeneic MHC class II molecules (dTregs) were obtained by stimulating CD4(+)CD25(+) cells from C57BL/6 mice (H-2(b)) with allogeneic DCs from BALB/c mice (H-2(d)). To generate Tregs that indirectly recognized allogeneic MHC class II molecules, dTregs were retrovirally transduced with TCR genes conferring specificity for H-2K(d) presented by H-2A(b) MHC class II molecules. The dual direct and indirect allospecificity of the TCR-transduced Tregs was confirmed in vitro. In mice, TCR-transduced Tregs, but not dTregs, induced long-term survival of partially MHC-mismatched heart grafts when combined with short-term adjunctive immunosuppression. Further, although dTregs were only slightly less effective than TCR-transduced Tregs at inducing long-term survival of fully MHC-mismatched heart grafts, histologic analysis of long-surviving hearts demonstrated marked superiority of the TCR-transduced Tregs. Thus, Tregs specific for allogeneic MHC class II molecules are effective in promoting transplantation tolerance in mice, which suggests that such cells have clinical potential.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18846251      PMCID: PMC2564608          DOI: 10.1172/JCI33185

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.

Authors:  M Hara; C I Kingsley; M Niimi; S Read; S E Turvey; A R Bushell; P J Morris; F Powrie; K J Wood
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

Review 2.  The role of peripheral T-cell deletion in transplantation tolerance.

Authors:  A D Wells; X C Li; T B Strom; L A Turka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-05-29       Impact factor: 6.237

3.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.

Authors:  R A Willemsen; M E Weijtens; C Ronteltap; Z Eshhar; J W Gratama; P Chames; R L Bolhuis
Journal:  Gene Ther       Date:  2000-08       Impact factor: 5.250

4.  Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection.

Authors:  P I Hornick; P D Mason; R J Baker; M Hernandez-Fuentes; L Frasca; G Lombardi; K Taylor; L Weng; M L Rose; M H Yacoub; R Batchelor; R I Lechler
Journal:  Circulation       Date:  2000-05-23       Impact factor: 29.690

5.  The technique for heterotopic cardiac transplantation in mice: experience of 3000 operations by one surgeon.

Authors:  M Niimi
Journal:  J Heart Lung Transplant       Date:  2001-10       Impact factor: 10.247

6.  Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy.

Authors:  R J Baker; M P Hernandez-Fuentes; P A Brookes; A N Chaudhry; H T Cook; R I Lechler
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

7.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

8.  Heterogeneity of T cell clones specific for a single indirect alloantigenic epitope (I-Ab/H-2Kd54-68) that mediate transplant rejection.

Authors:  K Honjo; X Y Xu; R P Bucy
Journal:  Transplantation       Date:  2000-11-27       Impact factor: 4.939

9.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.

Authors:  Olivier Joffre; Thibault Santolaria; Denis Calise; Talal Al Saati; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

10.  Identification of regulatory T cells in tolerated allografts.

Authors:  Luis Graca; Stephen P Cobbold; Herman Waldmann
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  115 in total

Review 1.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

2.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

Review 3.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

4.  Dendritic cells with TGF-β1 and IL-2 differentiate naive CD4+ T cells into alloantigen-specific and allograft protective Foxp3+ regulatory T cells.

Authors:  Hua Yang; Elaine Y Cheng; Vijay K Sharma; Mila Lagman; Christina Chang; Ping Song; Ruchuang Ding; Thangamani Muthukumar; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2012-03-27       Impact factor: 4.939

5.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

6.  Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization.

Authors:  Nina Pilat; Benedikt Mahr; Lukas Unger; Karin Hock; Christoph Schwarz; Andreas M Farkas; Ulrike Baranyi; Fritz Wrba; Thomas Wekerle
Journal:  JCI Insight       Date:  2016-05-19

7.  Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients.

Authors:  Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

8.  Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance.

Authors:  Hong Xu; Deborah M Ramsey; Shengli Wu; Larry D Bozulic; Suzanne T Ildstad
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

Review 9.  Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?

Authors:  Joseph Pidala; Claudio Anasetti
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 10.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.